Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.74 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.60 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.58 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315904 | 0.92 | KMT2A (0.84) | KMT2ANR1H4PLA2G4BSMPD1PLA2G2A | |
| SCHEMBL2455314 | 0.92 | KMT2A (0.84) | KMT2ANR1H4PLA2G4BSMPD1PLA2G2A | |
| SCHEMBL15766225 | 0.90 | KMT2A (0.82) | KMT2ANR1H4PLA2G4BSMPD1PLA2G2A | |
| SCHEMBL8086388 | 0.90 | KMT2A (0.82) | KMT2ANR1H4PLA2G4BSMPD1PLA2G2A | |
| SCHEMBL8080220 | 0.90 | KMT2A (0.82) | KMT2ANR1H4PLA2G4BSMPD1PLA2G2A | |
| SCHEMBL8081150 | 0.90 | KMT2A (0.82) | KMT2ANR1H4PLA2G4BSMPD1PLA2G2A | |
| SCHEMBL7822821 | 0.90 | KMT2A (0.82) | KMT2ANR1H4PLA2G4BSMPD1PLA2G2A | |
| SCHEMBL7047692 | 0.90 | KMT2A (0.82) | KMT2ANR1H4PLA2G4BSMPD1PLA2G2A | |
| SCHEMBL2887568 | 0.90 | KMT2A (0.82) | KMT2ANR1H4PLA2G4BSMPD1PLA2G2A | |
| SCHEMBL8082044 | 0.90 | KMT2A (0.82) | KMT2ANR1H4PLA2G4BSMPD1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022799-A1 | CARBONYLATION OF CONJUGATED DIENES | LUCITE INTERNATIONAL UK LIMITED (GB) | 2010-01-28 | — | — | US | claimed |
| CN-101563310-A | Carbonylation of conjugated dienes | LUCITE INT UK LTD (GB) | 2009-10-21 | — | — | CN | claimed |
| EP-2094635-A1 | CARBONYLATION OF CONJUGATED DIENES | Lucite International UK Limited (GB) | 2009-09-02 | — | — | EP | claimed |
| WO-2008075108-A1 | CARBONYLATION OF CONJUGATED DIENES | LUCITE INTERNATIONAL UK LIMITED (GB) | 2008-06-26 | — | — | WO | claimed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117304205-A | Benzimidazole ternary fused ring compound, pharmaceutically acceptable salt thereof and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-12-29 | — | — | CN | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| CN-104411707-B | Substituted phenylimidazopyrazoles and their use | 拜耳药业股份公司 | 2017-03-01 | — | — | CN | disclosed |
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2651417-B1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | CALCHAN LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| WO-2016091789-A1 | DERIVATIVES OF 2-PHENYL-7,7a-DIHYDRO-3aH-PYRANO[3,4-d]OXAZOLE-6(4H)-ONE | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2016-06-16 | — | — | WO | disclosed |
| US-5855971-A | Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film | NIPPON OIL COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0595995-A4 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0603786-A2 | Alkyl-substituted hydroquinone derivatives for use in ferro-electric liquid crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-06-29 | — | — | EP | disclosed |
| EP-0595995-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | ABBOTT LAB (US) | 1994-05-11 | — | — | EP | disclosed |
| WO-1993002037-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0507576-A1 | Polypropylene-based resin compositions | TOSOH CORPORATION (JP) | 1992-10-07 | — | — | EP | disclosed |
| US-3971863-A | Coated heat fusible injection moldable phenol-aldehyde pellets | GENERAL ELECTRIC COMPANY (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | KMT2A 4371/4885NR1H4 2049/4885PLA2G4B 1080/4885 |
| US-20100022799-A1 | CARBONYLATION OF CONJUGATED DIENES | CBR3, CBR1, CA5B | KMT2A 1801/4885NR1H4 1241/4885PLA2G4B 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.